RXRX Stock Overview

On the most recent trading day, Recursion Pharmaceuticals (RXRX) closed at $7.25, which is an increase of 0.14% compared to its last closing price.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $7.25, representing a +0.14% change from its previous close.

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

We have put together a list of the 30 Most Important AI Stocks according to Blackrock. In this article, we will examine how Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) compares to other AI stocks. In the third quarter of 2024, the investment giant Blackrock shared their views on the market outlook for artificial intelligence.

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (RXRX -0.31%) could be positioned to ride the ongoing wave of hype to great heights. Between its AI-first approach to designing new drugs and its positioning as a valuable collaborator for other companies, the company is worth paying attention to at a minimum.

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day.

The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared a clinical trial application (CTA) for a Phase 1 clinical trial of REC-3565, a potential best-in-class MALT1 inhibitor for B-cell malignancies. For REC-3565, the total addressable population could include a range of hematological indications, with approximately 41,000 relapsed and/or refractory (R/R) patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas in the US+EU5 annually.

Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.